2025
-
Third Plenary Session showcases exciting technologies driving innovation
Muhammad Shaalan Beg, MD, MBA, explained on Monday how clinical investigators can use new technologies to decentralize clinical trials, conducting portions of the trial at sites distanced from the principal investigator.
-
Presidential Address examines the necessary puzzle pieces to realize the promise of personalized medicine
Patricia M. LoRusso, DO, PhD (hc), FAACR, focused on one of her greatest passions, oncology drug development, during the Presidential Address.
-
Second Clinical Trials Plenary Session features new WRN, KRAS, and BRAF inhibitors
During the session on Sunday, Kathryn C. Arbour, MD, presented promising data on a novel KRAS G12D inhibitor in patients with lung cancer.
-
Third Clinical Trials Plenary Session highlights new targeted therapies for non-small cell lung cancer
John V. Heymach, MD, PhD, reported results on Monday from the first-in-human phase I Beamion LUNG-1 clinical trial of zongertinib in patients with previously treated HER2-mutated NSCLC.
-
AACR-ASCO joint session explores the potential of theranostics
The Monday joint session, chaired by ASCO President Robin Zon, MD, and AACR Immediate Past President Patricia M. LoRusso, DO, PhD (hc), FAACR, addressed opportunities in combining cancer therapy and diagnostic imaging modalities.
-
AACR-JCA joint session discusses disruption of differentiation in neural tumors
During the Monday session, speakers addressed tumorigenic mechanisms driving medulloblastoma and embryonic tumor with multilayered rosettes (ETMR), as well as glioblastoma.
-
Schedule Highlights from the Program Chairs: Tuesday, April 29
Don’t miss the Targeting the Cancer Ecosystem Plenary, Bringing Science to the Clinic Special Session, and more, say Program Committee Chairs Lillian L. Siu, MD, FAACR, and Matthew G. Vander Heiden, MD, PhD.
-
Opening Plenary showcases the continuum of innovation for impact
Catherine J. Wu, MD, FAACR, highlighted the promise of personalized neoantigen cancer vaccines—one of four exciting and emerging areas of science examined during the session.
-
First Clinical Trials Plenary studies support expansion of immunotherapy to more patients
Ravindra Uppaluri, MD, PhD, presented results that could soon prove practice-changing in patients with head and neck squamous cell carcinoma.
-
Plenary program to conclude Wednesday with predictive oncology, AACR Annual Meeting takeaways
The final day of the AACR Annual Meeting 2025 will feature two Plenary Sessions, including the morning Plenary Session on Opportunities in Predictive Oncology and a closing Plenary Session to showcase the meeting’s key highlights across the continuum of cancer research.